Welcome to our dedicated page for Denali Therapeut SEC filings (Ticker: DNLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics Inc. entered a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash, with closing subject to customary conditions including expiration of the Hart-Scott-Rodino waiting period. The voucher was awarded after the FDA’s accelerated approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome, in March 2026. Denali states that proceeds are intended to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases, building on its blood-brain barrier-crossing platform and expanding programs across multiple central nervous system indications.
Denali Therapeutics Inc. director Jay T. Flatley reported new equity awards in the form of common stock and stock options. He received 6,408 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock, with 100% of the RSUs vesting on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting.
Flatley was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring on June 3, 2036. Following these grants, he holds 22,628 shares directly, including 6,408 unvested RSUs, and 336,313 shares indirectly through The Flatley Family Trust, for which he serves as trustee. The filing does not show any open-market purchases or sales.
Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.
He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.
Denali Therapeutics director Steve E. Krognes reported equity awards and updated holdings. He received 6,408 shares of common stock in the form of Restricted Stock Units, which will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual stockholder meeting. He was also granted stock options for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule and an expiration date in 2036. Following these grants, he holds 38,202 shares directly and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee.
Denali Therapeutics director David P. Schenkein reported new equity awards. He received 6,408 Restricted Stock Units, each representing a contingent right to one share of common stock. These RSUs vest in full on the earlier of one year from grant or the day before the next annual stockholder meeting.
He also received a stock option for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule. After these grants, he directly holds 21,665 common shares, and additional common shares are held indirectly through the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust.
Denali Therapeutics Inc. director Nancy Thornberry reported routine equity compensation awards. She received 6,408 Restricted Stock Units, each tied to one share of common stock, which will fully vest on the earlier of one year from grant or the day before the next annual stockholder meeting.
She was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, with the same vesting schedule and expiration in 2036. Following these awards, she directly holds 31,125 shares of common stock, including the unvested RSUs.
Denali Therapeutics director Timothy Van Hauwermeiren received new equity awards as part of his compensation. He was granted 6,408 shares of common stock in the form of Restricted Stock Units (RSUs), each representing a contingent right to one share of Denali common stock.
All of these RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual meeting of stockholders. After this grant, he holds 17,040 RSUs in total, which are all unvested. He was also granted options to purchase 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring in 2036.
Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.
Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Denali Therapeutics Inc. director Julian C. Baker received equity-based compensation linked to Baker Brothers funds. The filing reports a grant of 6,408 restricted stock units payable in Denali common stock and 19,226 non-qualified stock options exercisable into common stock at a strike price of $19.66 per share. Both the RSUs and options vest on the earlier of June 3, 2027 or the day prior to Denali’s next annual meeting after June 3, 2026, subject to his continued board service. The transactions are reported as indirect interests of 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP holding voting and dispositive power. Felix and Julian Baker, the adviser and its general partner all disclaim beneficial ownership beyond their indirect pecuniary interests.
Denali Therapeutics Inc. reported the results of its annual stockholder meeting held on June 3, 2026. Of the 158,675,498 shares of common stock outstanding as of April 9, 2026, 137,986,127 were represented in person or by proxy, representing 86.96% of shares entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 annual meeting: Jennifer Cook, David Schenkein, M.D., and Ryan Watts, Ph.D. Each received more votes “for” than “withheld,” with Ryan Watts, Ph.D. receiving 121,220,572 votes in favor.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 137,516,267 votes for, 420,305 against, and 49,555 abstentions. In an advisory vote, stockholders approved the compensation of the named executive officers, with 117,038,745 votes for and 7,088,810 against.